R&D News | pharmaphorum

News

After CagriSema blow, Novo reveals data for obesity 'triple'

Novo Nordisk's triple-action obesity therapy UBT251, licensed in a $2bn deal last year, achieved almost 20% weight loss in a mid-stage trial.

News

MSD splits pharma business, hiving off oncology

MSD is separating its cancer and non-cancer pharma operations as it prepares for the looming loss of patent protection for $31bn blockbuster Keytruda.

News

FDA maps new regulatory route for ultra-rare diseases

The FDA has sketched out its 'plausible mechanism' regulatory pathway for individualised therapies that treat ultra-rare diseases.

News

Gilead buys cell therapy partner Arcellx for up to $7.8bn

Gilead has shored up its position in cell therapies with a deal to acquire Arcellx, taking full control of their partnered multiple myeloma CAR-T.

News

Cartoon graphic of a woman with glasses holding thought bubbles in the palm of either hand, one with a check and one with a cross

Head-to-head trial dents Novo Nordisk's obesity hopes

Novo Nordisk slumps as its two-drug combination for weight loss, CagriSema, performs less well than Eli Lilly's rival Zepbound in a comparative trial.

News

Elderly man talks to younger female nurse beside a Grail screening vehicle

Grail's multi-cancer test fluffs its lines in UK trial

Grail's Galleri blood test for cancer screening missed the mark in the much-anticipated NHS-Galleri trial, wreaking havoc with the firm's share price.

After CagriSema blow, Novo reveals data for obesity 'triple'

MSD splits pharma business, hiving off oncology

FDA maps new regulatory route for ultra-rare diseases

Gilead buys cell therapy partner Arcellx for up to $7.8bn

Head-to-head trial dents Novo Nordisk's obesity hopes

Grail's multi-cancer test fluffs its lines in UK trial

Zuckerberg, Chan's Biohub launches protein 'world model'

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks